Intermediate-term outcome of variable dose mitomycin C filtering surgery

J. C. Cheung, M. M. Wright, S. Murali, J. E. Pederson

Research output: Contribution to journalArticlepeer-review

115 Scopus citations

Abstract

Purpose: Trabeculectomy with adjunctive mitomycin C is associated with high success rates in studies with follow-up of less than 1 year. This report evaluates the visual and intraocular pressure (IOP) outcome in eyes after trabeculectomy with adjunctive mitomycin C 1 to 3 years after surgery in a predominantly white group (98.1%). Methods: The records of 157 eyes of 157 consecutive patients, aged 18 or older, who underwent mitomycin C trabeculectomies for uncontrolled glaucoma of various causes were reviewed. All surgeries were performed between April 1991 and June 1993. The concentration of mitomycin C varied from 0.2 to 0.5 mg/ml and was applied for 30 seconds to 5 minutes (only one patient received 0.2 mg/ml). Of the 157 eyes, 110 eyes were at high risk for failure (previous surgeries or inflammatory glaucoma). Thirty-nine eyes had preoperative IOP ≤ 21 mmHg. Results: The mean preoperative IOP was 29.4 ± 10.3 mmHg. This was reduced to 13.0 ± 7.6 mmHg at 1 year, 11.5 ± 6.4 mmHg at 2 years, and 13.4 ± 7.3 mmHg at 3 years. Cumulative survival rate by life-table analysis was 94.2% ± 1.9% at 1 year, 92.1% ± 2.4% at 2 years, and 88.7% ± 4.0% at 3 years, where failure was defined as reoperation for control of IOP. Complications included cataract formation-progression (n = 31), hyphema (n = 26), choroidal detachment (n = 21), hypotony maculopathy (n = 5), and endophthalmitis (n = 2). Vision deteriorated in 29 eyes and improved by 2 or more Snellen visual acuity lines in 29 eyes. Conclusion: The IOP reduction after mitomycin C filtering surgery is sustained in the intermediate-term, 1 to 3 years, follow-up period.

Original languageEnglish (US)
Pages (from-to)143-149
Number of pages7
JournalOphthalmology
Volume104
Issue number1
DOIs
StatePublished - Jan 1 1997

Fingerprint Dive into the research topics of 'Intermediate-term outcome of variable dose mitomycin C filtering surgery'. Together they form a unique fingerprint.

Cite this